Dynastat

RSS

parecoxib

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Dynastat. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Dynastat.

This EPAR was last updated on 11/10/2018

Authorisation details

Product details
Name
Dynastat
Agency product number
EMEA/H/C/000381
Active substance
parecoxib sodium
International non-proprietary name (INN) or common name
parecoxib
Therapeutic area (MeSH)
Pain, Postoperative
Anatomical therapeutic chemical (ATC) code
M01AH04
Publication details
Marketing-authorisation holder
Pfizer Europe MA EEIG
Revision
27
Date of issue of marketing authorisation valid throughout the European Union
22/03/2002
Contact address

Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Product information

28/09/2018 Dynastat - EMEA/H/C/000381 - T/0073

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Anti inflammatory and antirheumatic products

Therapeutic indication

For the short-term treatment of postoperative pain in adults.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating